Ponezumab: Difference between revisions
CSV import |
No edit summary |
||
| Line 23: | Line 23: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 13:09, 18 March 2025
Ponezumab is a monoclonal antibody designed for the treatment of Alzheimer's disease. It was developed by Pfizer and is currently in the clinical trial phase. Ponezumab targets amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients.
History[edit]
Ponezumab was first developed by Pfizer in the early 2000s. The drug entered Phase I clinical trials in 2005, and Phase II trials in 2008. In 2012, Pfizer announced that Ponezumab had failed to meet its primary endpoints in a Phase II trial, but the company continued to investigate its potential for treating Alzheimer's disease.
Mechanism of Action[edit]
Ponezumab is a monoclonal antibody that binds to amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients. By binding to amyloid beta, Ponezumab is thought to prevent the formation of these plaques, thereby slowing the progression of Alzheimer's disease.
Clinical Trials[edit]
Ponezumab has undergone several clinical trials to assess its safety and efficacy in treating Alzheimer's disease. In a Phase II trial, Ponezumab failed to meet its primary endpoints, but showed some promise in slowing cognitive decline in patients with mild-to-moderate Alzheimer's disease. Pfizer is currently conducting further trials to investigate the potential of Ponezumab in treating Alzheimer's disease.
